Los Angeles Capital Management
PCVX icon

Los Angeles Capital Management’s Vaxcyte PCVX Stock Holding History

Los Angeles Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.7K Sell
769
-821
-52% -$44.6K ﹤0.01% 1533
2026
Q1 		$92.4K Sell
1,590
-20,417
-93% -$1.11M ﹤0.01% 1353
2025
Q4 		$985K Sell
22,007
-4,896
-18% -$219K ﹤0.01% 626
2025
Q3 		$969K Sell
26,903
-12,559
-32% -$416K ﹤0.01% 711
2025
Q2 		$1.28M Buy
+39,462
New +$1.29M ﹤0.01% 583
2024
Q4 		– Sell
-8,895
Closed -$1.02M – 1213
2024
Q3 		$1.02M Buy
+8,895
New +$802K ﹤0.01% 649

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Los Angeles Capital Management's PCVX Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Vaxcyte (PCVX) stake by 52% in Q2 2026, selling an estimated $44.6K and leaving 769 shares worth $44.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1533.

Los Angeles Capital Management first reported a position in PCVX in Q3 2024 and has held it in 6 quarters since. The position peaked at $1.28M in Q2 2025. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Los Angeles Capital Management held 769 shares of Vaxcyte worth $44.7K as of Q2 2026.
  • Los Angeles Capital Management sold 821 Vaxcyte shares in Q2 2026, an estimated $44.6K.
  • Vaxcyte made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1533 holding.
  • Los Angeles Capital Management first reported a position in Vaxcyte in Q3 2024 and has held it in 6 quarters since.
  • Los Angeles Capital Management's Vaxcyte position peaked at $1.28M in Q2 2025.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.